Zepp Health Corporation Sponsored ADR (NYSE:ZEPP) Short Interest Down 18.9% in April

Zepp Health Corporation Sponsored ADR (NYSE:ZEPP) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 375,680 shares, a decrease of 18.9% from the March 31st total of 463,069 shares. Based on an average daily trading volume, of 85,099 shares, the days-to-cover ratio is presently 4.4 days. Currently, 4.0% of the company’s shares are sold short.

Zepp Health Stock Up 4.9%

NYSE:ZEPP traded up $0.86 during mid-day trading on Friday, hitting $18.33. The stock had a trading volume of 50,340 shares, compared to its average volume of 66,168. The stock has a 50-day simple moving average of $16.18 and a two-hundred day simple moving average of $24.66. The company has a market capitalization of $265.74 million, a PE ratio of -7.30 and a beta of 2.00. Zepp Health has a twelve month low of $2.22 and a twelve month high of $61.85. The company has a current ratio of 1.02, a quick ratio of 0.77 and a debt-to-equity ratio of 0.28.

Institutional Trading of Zepp Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FIL Ltd purchased a new position in shares of Zepp Health during the fourth quarter worth approximately $16,858,000. Millennium Management LLC grew its position in shares of Zepp Health by 49.1% during the fourth quarter. Millennium Management LLC now owns 366,826 shares of the company’s stock worth $9,882,000 after acquiring an additional 120,750 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Zepp Health by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 295,967 shares of the company’s stock worth $7,974,000 after acquiring an additional 44,619 shares during the last quarter. Trivest Advisors Ltd purchased a new position in shares of Zepp Health during the third quarter worth approximately $13,503,000. Finally, Balyasny Asset Management L.P. grew its position in shares of Zepp Health by 46.9% during the fourth quarter. Balyasny Asset Management L.P. now owns 202,775 shares of the company’s stock worth $5,463,000 after acquiring an additional 64,692 shares during the last quarter. Institutional investors and hedge funds own 52.61% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on ZEPP shares. Fundamental Research set a $56.28 target price on shares of Zepp Health and gave the company a “buy” rating in a research report on Wednesday, April 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zepp Health in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $56.28.

About Zepp Health

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.